GlaxoSmithKline ( GlaxoSmithKline )


GlaxoSmithKline's picture

GlaxoSmithKline started operations on 1 January 2001 following the merger of GlaxoWellcome plc and SmithKline Beecham plc, but our combined histories go back much further than that. Find out about the many products and mergers that led to the GSK we know today.

GlaxoSmithKline press release, blog etc

07/12/2018 - 17:39 James Ford appointed GSK General Counsel
07/12/2018 - 17:08 Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
07/12/2018 - 15:41 US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria
06/26/2018 - 22:07 Infants may now be protected against Meningitis B with fewer doses, adding flexibility to vaccination schedules
06/13/2018 - 22:11 ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naive patients
06/13/2018 - 10:19 GSK presents new results showing low rates of organ damage with long term use of Benlysta
06/11/2018 - 19:49 GSK announces changes to Vaccines and Global Manufacturing & Supply leadership
06/01/2018 - 12:46 GSK completes Consumer Healthcare buyout
05/29/2018 - 06:24 GSK submits regulatory application in Japan for once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD
05/21/2018 - 10:11 GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma
05/21/2018 - 04:41 ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
05/21/2018 - 03:26 Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control
05/16/2018 - 03:04 GSKs industry-leading respiratory research and scientific innovation showcased at ATS conference
05/09/2018 - 08:10 Simon Dingemans, Chief Financial Officer, to retire from GSK
04/24/2018 - 10:16 Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD
04/18/2018 - 15:59 Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD
04/18/2018 - 08:15 GSK appoints Kevin Sin as new SVP and Head of Worldwide Business Development for R&D
04/12/2018 - 01:36 GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics